D.C. Circuit Rejects Mylan's Bid To Make Generic Duragesic

Law360, New York (December 7, 2004, 12:00 AM EST) -- A U.S. appeals court in Washington, D.C. has rejected Mylan Laboratories' bid to market a generic version of Johnson & Johnson's Duragesic pain-relief skin patch.

The United States Court of Appeals for the District of Columbia Circuit upheld a June decision by the Food and Drug Administration and affirmed another court ruling that allowed Johnson & Johnson to retain exclusive rights to Duragesic until January as a reward for testing the effects of the drug on children.

The D.C. Circuit held that the FDA did not...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.